Connect with us

CBD News

US Patent Office (USPTO) Releases CBD Trademark Guidelines in Light of 2018 Hemp Farm Bill



Last week, the U.S. Patent and Trademark Office (USPTO) issued a memo concerning CBD products. The memo, titled Examination of Marks for Cannabis and Cannabis-Related Goods and Services and Enactment of the 2018 Farm Bill provides insight into how the trademark office will treat such applications.

The memo, which can be read in full here, begins by addressing the preliminary issue, which is that goods or services seeking registration with the USPTO must comply with federal law, regardless of the legality of the activities under state law. The memo identifies the federal laws that the products or services must comply with.

The memo continues to focus on this point, stating in the body of the memo “the USPTO refuses registration when an application identifies goods encompassing CBD or other extracts of marijuana because such goods are unlawful under federal law and do not support valid use of the applied-for mark in commerce.” Under federal law, cannabis is illegal.

It seems that applications filed on or after December 20, 2018, which are impacted by the 2018 Farm Bill, may be treated slightly different. The memo states, “For applications filed on or after December 20, 2018 that identify goods encompassing cannabis or CBD, the 2018 Farm Bill potentially removes the [Controlled Substances Act] as a ground for refusal of registration, but only if the goods are derived from ‘hemp.’ Cannabis and CBD derived from marijuana (i.e., Cannabis sativa L. with more than 0.3% THC on a dry-weight basis) still violate federal law, and applications encompassing such goods will be refused registration regardless of the filing date.”

In addition, the memo discusses that the 2018 Farm Bill does not make all CBD or hemp-derived products lawful. It states, “Applicants should be aware that even if the identified goods are legal under the CSA, not all goods for CBD or hemp-derived products are lawful following the 2018 Farm Bill. Such goods may also raise lawful-use issues under the Federal Food Drug and Cosmetic Act.”

Applicants who filed before December 20, 2018 and that identified goods encompassing CBD or other cannabis products, the USPTO can reject their registration due to the lawful use or lack of bonafide intent to use in lawful commerce under the Controlled Substances Act.

The memo further indicates,

“Because of the new legal definition of “hemp” under the 2018 Farm Bill, the applicant will also be required to amend the identification of goods to specify that the CBD or cannabis products contain less than 0.3% THC. If the applicant elects to amend the application, the examining attorney will conduct a new search of the USPTO records for conflicting marks based on the later application filing date. TMEP §§206.01, 1102.03. The examining attorney will also advise the applicant that, in lieu of amending the application, it may elect to abandon the subject application and file a new application. Alternatively, the applicant may respond to the stated refusal by submitting evidence and arguments against the refusal.”

All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.

Jane is a regular contributor who learned about the great benefits of CBD a few years ago after starting it herself. Impressed by its effects, she's interested in helping others learn about options that can be helpful for them.

Continue Reading

Ultimate CBD Guide


ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email

Copyright © 2020 | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.